STRATA Skin Sciences, Inc. (SSKN): Nasdaq/NYSE listing notice — STRATA Skin Sciences receives NASDAQ bid price deficiency notice; appoints Dr. Uri Geiger as Chairman

STRATA Skin Sciences, Inc.

Received NASDAQ notice on June 29, 2023 for bid price below $1.00 for 30 consecutive business days.
Has 180 days (until Dec 26, 2023) to regain compliance by closing at $1.00+ for 10 consecutive trading days.
Dr. Uri Geiger appointed Chairman effective July 3, 2023; William Humphries steps down but remains on Board.
Humphries transition due to becoming CEO of Alcami; Geiger has 20+ years medtech experience.

item 3.01 item 7.01 item 8.01 item 9.01 item 2.02

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

STRATA Skin Sciences, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 29, 2023, STRATA Skin Sciences, Inc. (the "Company") received written notification (the "Notice") from The NASDAQ Stock Market ("NASDAQ") that the closing bid price of its common stock had been below the minimum $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued listing on the NASDAQ Capital Market under NASDAQ Listing Rule 5550(a)(2). The Notice provides the Company with an initial period of 180 calendar days, or until December 26, 2023, to regain compliance with the listing rules. The C

View on SEC.gov

Browse all listing & compliance notices →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001051514-23-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.